Expert Perspectives on Therapeutic Advances to Improve Treatment, Clinical Outcomes, and Quality of Life of Veterans With NSCLC

Use this on-demand Webcast downloadable slideset and clinical resource PDF to review critical updates in the care of veterans with advanced NSCLC. Based on the latest guidelines and clinical data learn how to identify the best candidates for immunotherapy use molecular profiling in therapeutic decision making and manage treatment-related toxicities.

Share

Program Content

Activities

NSCLC Management
Expert Perspectives on Therapeutic Advances to Improve Treatment, Clinical Outcomes, and Quality of Life of Patients With NSCLC
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: November 13, 2018

Expires: November 12, 2019

Activities

NSCLC Management Guide
Overview of Advanced NSCLC Management: A Clinician’s Guide and Resource
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: November 08, 2018

Expires: November 07, 2019

Activities

Expert Perspectives on Therapeutic Advances in NSCLC
Expert Perspectives on Therapeutic Advances to Improve Treatment, Clinical Outcomes, and Quality of Life of Veterans With NSCLC
Multimedia
Congratulations: You achieved a completion on 04/09/2022

Released: March 18, 2019

Expires: March 16, 2020

Faculty

cover img faculity

Jonathan Dowell, MD

Associate Professor of Internal Medicine
Department of Hematology/Oncology
University of Texas Southwestern Medical Center
Dallas, Texas

cover img faculity

Melissa L. Johnson, MD

Assistant Professor
Division of Hematology/Oncology
Robert H. Lurie Comprehensive Cancer Center 
Northwestern University
Assistant Attending
Divison of Hematology/Oncology
Northwestern Memorial Hospital
Chicago, Illinois

cover img faculity

Joshua Bauml, MD

Instructor, Division of Hematology/Oncology
Perelman School of Medicine at the University of Pennsylvania
Staff Physician
Philadelphia VA Medical Center
Philadelphia, Pennsylvania

Provided by

ProCE Banner

Supporters

This activity is supported by educational grants from

AstraZeneca Pharmaceuticals

Celgene TEXT Only